We described and compared breast and ovarian screening practices in the 2-year period following test result disclosure in female non-carriers from BRCA1/2 mutation-positive families living in two countries, France and Quebec, Canada, which provide universal health care. Four hundred and two (France n¼293; Quebec n¼109) unaffected female non-carriers from BRCA-proven mutation families provided information about the uptake of mammography, clinical breast examination, breast self-examination, and ovarian ultrasounds using self-administered questionnaires. The frequency of screening practices between study cohorts were compared using logistic regression. Annual mammography was conducted in 23 and 43% of French and Quebecer women participants o50 years of age, respectively (adjusted odds ratio (aOR)¼2.72; 95% confidence interval (CI), 1.08-6.81). In women Z50 years of age, mammography was conducted in 49 and 65% of French and Quebecer participants (aOR¼1.77; 95% CI, 0.07-4.51). Overall, 33% of French women and 39% of Quebecer women underwent at least one ovarian ultrasound during the 2-year period following BRCA1/2 test result with no significant difference between cohorts of women o50 years of age. Among older women, Quebecers reported more frequently than French women that they had undergone ultrasound once (aOR¼3.00; 95% CI, 1.02-8.83). The frequency of cancer screening practices for female non-carriers from BRCA1/2 mutationpositive families in both France and Quebec exceeded those recommended for similarly aged women in the general population. Our findings highlight the need for clearcut recommendations on the follow-up of women from BRCA1/2 families who are not themselves carriers of a BRCA1/2 mutation.
INTRODUCTION
Women from BRCA1/2 mutation-positive families, but who are noncarriers, are not considered to have a high risk for breast and ovarian cancer. [1] [2] [3] Despite some controversy about the magnitude of residual risk of breast cancer based on family history, 2,4 female non-carriers from BRCA1/2 mutation-positive families are currently encouraged to adopt the same screening practices as those recommended for women of their age in the general population. 1, 5 Information with regard to cancer screening practices among non-carriers from BRCA1/2 mutation-positive families is scarce and inconsistent. An Australian study evaluating women who underwent BRCA1/2 testing in a research context showed that mutation non-carriers overuse screening. 6 In contrast, an UK clinical cohort study revealed that over one-third of non-carriers Z50 years of age had not had a mammogram within 3 years of follow-up, suggesting that some mutation non-carriers derive false reassurance from the genetic test results and avoid cancer screening. 7 In countries with public health care, such as France and Canada, over-screening entails inappropriate use of public resources allocated to health care. As genetic testing for cancer susceptibility becomes more commonplace in clinical medicine, it is imperative to determine whether individuals undergoing testing benefit from such practices and are making optimum use of health resources corresponding to their actual risk levels. Risk management and follow-up recommendations for BRCA1/2 mutation carriers, which are available in both France and Canada, 8, 9 suggest the same screening rates for female non-carriers from BRCA mutation-positive families as those applying to the general population. Briefly, in both countries, all women of age 50-69 years should undergo mammography every 2 years. 10, 11 Although controversy surrounds the benefits of mammography for women of age 40-49 years, they can be granted access after discussing the risks and benefits with their physician. Routine mammographic screening is not recommended for women o40 years of age. Clinical breast examination (CBE) and breast self-examination (BSE) are complementary to mammography. In both countries, annual CBE is recommended for women of age 50-69 years, but BSE is not recommended as a routine method of breast cancer surveillance. Ultrasound (US) and CA-125 test are not recommended for ovarian cancer screening in either country. In this study, we describe and compare the cancer screening practices of female non-carriers from BRCA1/2 mutation-positive families in two countries that offer universal access to health care, France and Quebec.
METHODS Participants
Participants from France were identified through a companion psychosocial study of the GENEPSO cohort. 12 The GENEPSO cohort included BRCA1/2 mutation carriers recruited during routine consultation from the year 2000 to present at 26 cancer genetics clinics belonging to the French National Federation of Cancer Centres' Cancer Genetic Network. The companion psychosocial cohort study enrolled, through year 2006, both unaffected carriers and non-carriers from BRCA mutation-positive families identified in the GENEPSO cohort. Participants from Quebec were recruited from the INHERIT BRCAs research program, which provided French Canadian individuals with BRCA1/2 testing. Details concerning the study design and population are available. 13, 14 In the cohorts from both countries, women eligible for this study were non-carriers from BRCA-positive families who were aware of their test result, had never had cancer, and were younger than 70 years of age at result disclosure. This study was approved by the Institutional Ethics Review Boards of the participating institutions, and all participants signed informed consent forms.
Data collection
Information with regard to the yearly frequency of breast and ovarian cancer screening practices during the 2-year period following result disclosure was collected similarly in both cohorts using self-administered, mail-in questionnaires that were completed 1 year post-disclosure in both groups, and then 1 and 2 years later by the French and Quebecer cohorts, respectively. The questions asked concerned the yearly frequency of mammography, CBE, BSE, US, and in the Quebec sample only, the CA-125 blood test. Item formulation differed slightly between the two surveys. To allow comparability between the two cohorts, the responses collected after each 1-year period were dichotomised to determine if a woman underwent a given test during that period. Reponses about year 1 and year 2 were then combined into a three-category variable referred to as 'annually' , 'once during the 2-year period' , and 'none' , which reflected the frequency of the screening practices during the follow-up period. In the case of BSE, the three categories were 'monthly or more often' , 'less often than monthly' , and 'never' .
All participants provided socio-demographic details, including age, education, marital and employment status, and parity. Although questions on several psychosocial variables were included in both surveys, only perceived lifetime breast cancer risk, as assessed on a five-point Likert scale in the first 6 months following test result disclosure, was measured in a sufficiently similar way in the two cohorts to be included in this analyses. Medical information such as personal and familial cancer history was obtained from the participants' medical (France) or research project (Quebec) files.
Analyses
The w 2 test was used to compare the socio-demographic data, cancer risk perception, familial history of cancer, and the timing of result disclosure in participants from France and Quebec. The proportions of women in each cohort who underwent a given test annually, once during the 2-year period, or never were calculated by age strata. BSE proportions were calculated on the basis of monthly frequency. Over-screening, according to French and Canadian recommendations for women from the general population, was defined as undergoing mammography before the age of 50 years or at a rate of more than once every 2 years after the age of 50 years. Testing by US or CA-125 was also considered over-screening. As no precise recommendations exist with regard to CBE and BSE, no over-screening criteria were defined for these practices.
Crude and adjusted comparisons on screening practices between the two cohorts were assessed by the odds ratios (ORs) with 95% confidence intervals, using polytomic logistic regression models. The potential confounding effects of several variables were assessed by comparing the crude and adjusted models. Potential confounders included socio-demographics, breast cancer risk perception, family history of breast and ovarian cancer, and the timing of result disclosure. Statistical analyses were performed using the SAS 9.1 software. 15 All significance levels were two-sided.
RESULTS

Participants
The 2-year questionnaire was completed by 293 (83%) of the 354 eligible unaffected non-carriers who participated in the psychosocial GENEPSO cohort companion study. The 3-year questionnaire was completed by 109 (81%) of the 134 eligible unaffected women with truly negative results who participated in the Quebec psychosocial study.
Patient characteristics differed between the two cohorts ( Table 1 ). The French participants were younger than the Quebecers. Even though women who perceived their breast cancer risk as high or very high accounted for similar percentages within both cohorts, the Quebecer cohort contained a higher percentage of women who perceived their breast cancer risk as low or very low. Quebecers had a higher number of first-degree relatives affected by breast cancer as compared with the French women, whereas the opposite was true with regard to family history of ovarian cancer. French women received more recent disclosure of the BRCA1/2 test compared with the Quebec women.
Screening practices
France. Nearly one-half of the French women in the 50-69 age group underwent annual mammography ( Table 2) . During the 2-year follow-up period, 78 and 44% of women in the 40-49 age group and the 30-39 age group, respectively, had at least one mammogram ( Table 2 ). The overall rate of over-screening by mammography was 50% in the French cohort ( Figure 1 ). An annual CBE was conducted in over 61% of French women in all age groups, whereas 11% of women did not have a CBE within the 2-year follow-up period. The overall proportion of women reporting no BSE was 35%. Thirty-three percent of French women underwent at least one US during the 2-year follow-up period with little proportion variation among age groups.
Quebec. Approximately two-thirds of the Quebecer women Z40 years of age underwent an annual mammogram, and 40% of women of age 30-39 years had a mammogram at least once during the 2-year follow-up period ( Table 3 ). The overall rate of over-screening by mammography in the Quebecer group was 64% (Figure 1 ). An annual CBE was conducted for most women (78%) in all age groups, whereas only 6% did not have a CBE during the 2-year follow-up period. Overall, 39% of Quebecers underwent US at least once during the 2-year follow-up period with fairly consistent proportion across age groups. The rate of over-screening by CA-125 blood test during the 2-year follow-up period was 30%, with 25% of women of age 50-69 years undergoing this test annually.
Comparisons between France and Quebec. With regard to breast cancer screening practices, the greatest difference between the two cohorts was for women r49 years of age (Table 4 ). In this younger age group, the proportions of Quebecers who had annual mammography, annual CBE, and reported performing BSE were significantly higher than those of the French women. These differences persisted after controlling for age, breast cancer risk perception, and family Cancer screening practices of BRCA1/2 non-carriers M Dorval et al history of breast cancer. In women of age Z50 years, the only difference detected was for CBE, adjusted OR showing more frequent use of CBE at least once during the 2-year follow-up period by Quebecers as compared with French women.
With regard to the frequency of US among women r49 years of age, no difference was observed between cohorts. Among older women, however, there was more frequent occurrence of US once during the 2-year follow-up period for Quebecers as compared with French women.
Comparisons with women from the general population. To determine whether screening was also overused by women in the general population in the two countries, we compared the rates of mammography over a 2-year period as reported in population-based surveys 16, 17 with those observed in our cohorts of true non-carriers. No population data were available with respect to ovarian cancer screening. In both countries and for all age groups, the rates of mammography were substantially higher among non-carriers than among women from the general population (Table 5) .
DISCUSSION
This comparative study examining cohorts from France and Quebec shows screening practices that exceed those recommended for similarly aged women of the general population in a substantial number of Cancer screening practices of BRCA1/2 non-carriers M Dorval et al female non-carriers from BRCA mutation-positive families. Specifically, over one-half of French and Quebec non-carriers underwent unnecessary mammography during the 2-year period following result disclosure. In younger women, however, Quebecers were more frequently screened for breast cancer than French women. Ovarian US screening was also overused in 33 and 39% of non-carriers in France and Quebec, respectively. One possible explanation for differences in practices between the two cohorts concerns the knowledge of physicians with respect to breast cancer screening. In France, guidelines for the management of BRCA1/2 carriers were available 8 years before the Canadian recommendations. 8, 9, 18 Within the French recommendations are specific statements suggesting that non-carriers from families with a proven BRCA1/2 mutation have cancer risks similar to those of individuals in the general population. The Canadian recommendations on the follow-up of women having a family history of breast cancer do not clearly take into account the possibility that these women can obtain truly negative BRCA1/2 test results. Therefore, it is possible that Quebec physicians may have been reluctant to reduce the breast cancer screening rates of these non-carrier women from BRCApositive families to those of women in the general population to fulfil their medical/ethical/legal obligations. Owing to their proximity to the United States, Quebec physicians may also be influenced by the American guidelines, which recommend annual mammography for women aged Z40 years. The high frequency of ovarian cancer screening observed in both cohorts is intriguing. Although the frequency of US was similar in France and Quebec, the reasons behind over-screening may differ between the two countries because of variations in accessibility and attitudes toward US screening. For example, France has the highest number of recommended US scans of all European countries in the context of prenatal screening, 19 with 47% of women averaging 4.5 US screens during pregnancy in 2003. 20 In contrast, the Re´gie de l'Assurance-Maladie du Québec reimburses for only two US scans during pregnancy, with accessibility being limited by a shortage of radiologists. 21 The high rates of US observed in the two populations deserve closer examination because ovarian cancer screening is not recommended, especially among women with negative BRCA1/2 test results.
Several limitations should be considered when assessing these findings. First, no information was collected in either the French or the Quebec survey with regard to the actual screening recommendations provided to women after they received their BRCA1/2 test result. Therefore, the reasons for the intensive cancer screening practices of non-carriers from BRCA mutation-positive families are unknown. Second, the screening practice information collected was based on selfreporting, and consequently they are subject to memory and social desirability biases. Although self-reports about screening practices are generally accurate, 22 some women may have overestimated their frequency when asked to report them retrospectively. 23 Third, comparison was made between two groups of women who were tested in different contexts. Although statistical comparisons were modelled using potential confounding factors for which the data were sufficient, the possibility of residual confounding cannot be ruled out.
When considering the public health impact of over-screening by female non-carriers from BRCA mutation-positive families, financial, psychosocial, and physical implications should be considered. In countries where health care is available to all, over-screening by true non-carriers constitutes inappropriate use of public resources. Furthermore, false-positive screening test results often lead to unnecessary invasive diagnostic procedures that entail additional costs, anxiety, and reluctance to participate in or withdraw from screening programmes. [24] [25] [26] It has been estimated that 50% of women will have at least one false-positive test result for every 10 mammograms they undergo. 27 Rates of false-positive test results are even higher in ovarian cancer screening. 28 Given the intense screening practices of women with negative BRCA1/2 test results, further research is required on the psychosocial impact of false-positive screening results in this subgroup of women, who may be vulnerable to psychological distress. Moreover, it has not been established whether mammographic screening is safe before 40 years of age. The lifetime risk of radiation-induced breast cancer may be higher in women who start having mammograms at a relatively young age because of extended total exposure. 29, 30 As our ability to estimate individual breast cancer risk improves through understanding additional genetic and environmental factors involved in familial clustering, it may eventually be feasible to target female non-carriers from BRCA mutation-positive families who may benefit from more intensive screening. 31 Our findings have implications for the follow-up of women from families that carry BRCA1/2 mutations, but for whom genetic test results are negative. First, because most of these women will be referred to their primary care physicians and gynaecologists for future risk management, risk information based on the genetic test must be Cancer screening practices of BRCA1/2 non-carriers M Dorval et al properly transmitted to the usual care settings. Second, clearcut recommendations are needed on the follow-up of women from BRCA1/2 families who do not carry the familial mutation. Third, such recommendations should be accompanied by continuous education of primary care physicians with respect to the rapidly evolving field of cancer genetics. Fourth, further research is required to develop and assess methods of fostering optimum use of screening in the context of cancer genetic testing. One challenge is to provide true noncarriers of familial BRCA1/2 mutations with complete information about the possible benefits and risks involved in further screening, without over-reassuring them.
